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Members of the tripartite motif (TRIM) protein family
of RING E3 ubiquitin (Ub) ligases promote innate im-
mune responses by catalyzing synthesis of polyubi-
quitin chains linked through lysine 63 (K63). Here,
we investigate the mechanism by which the TRIM5a
retroviral restriction factor activates Ubc13, the K63-
linkage-specific E2. Structural, biochemical, and
functional characterization of the TRIM5a:Ubc13-Ub
interactions reveals that activation of the Ubc13-Ub
conjugate requires dimerization of the TRIM5a RING
domain. Our data explain how higher-order oligomer-
ization of TRIM5a, which is promoted by the interac-
tion with the retroviral capsid, enhances the E3 Ub
ligase activity of TRIM5a and contributes to its antire-
troviral function. This E3 mechanism, in which RING
dimerization is transient and depends on the interac-
tion of the TRIM protein with the ligand, is likely to be
conserved in many members of the TRIM family and
mayhaveevolved to facilitate recognitionof repetitive
epitope patterns associated with infection.INTRODUCTION
TRIM proteins are defined by a conserved domain pattern, in
which the RING module is located at the N terminus of the pro-
tein followed by one or two B-box domains and then by a
coiled-coil segment. The C-terminal portion of TRIM proteins
usually contains a protein-protein interaction module, most
commonly the SPRY/B30.2 domain found in almost half of the
human TRIM family members (Sardiello et al., 2008). TRIMs are
increasingly recognized for their involvement in regulation of
innate immunity, and their role in innate antiviral defenses is
particularly well established (McNab et al., 2011). This study is
focused on the TRIM5a retroviral restriction factor, which was
identified as a potent restrictor of HIV infection in a screen of788 Cell Reports 12, 788–797, August 4, 2015 ª2015 The AuthorscDNA from the rhesus monkey, a non-permissive host for
HIV-1 infection (Stremlau et al., 2004).
High-resolution structures of the individual TRIM domains
have now been determined by X-ray crystallography and NMR
(Biris et al., 2012; Diaz-Griffero et al., 2009; Goldstone et al.,
2014; Lienlaf et al., 2011; Sanchez et al., 2014). TRIM5a forms
a stable, coiled-coil-mediated dimer in solution (Kar et al.,
2008; Langelier et al., 2008). Crystal structures of the TRIM25
and TRIM5a coiled-coil regions reveal the antiparallel coiled-
coil hairpin architecture of the dimer, in which the RING and
B-box domains of each monomer are located on the opposing
ends of the rod-shaped, 170-A˚-long dimer, with the two SPRY
domains positioned close to the middle of the coiled-coil rod
(Goldstone et al., 2014; Sanchez et al., 2014).
The mechanism of TRIM5a-mediated restriction is not fully
understood, but several biochemical properties of TRIM5a are
known to be important. First is the capacity of TRIM5a to bind
directly to the assembled capsid protein of the mature viral
core (Diaz-Griffero et al., 2006a; Sebastian and Luban, 2005;
Stremlau et al., 2006) in an interaction mediated by the C-termi-
nal SPRY domain. Differences in the amino-acid composition of
primate TRIM5a SPRY domain variants are major determinants
of primate immunodeficiency viruses’ host tropism (Ohkura
et al., 2006; Song et al., 2005).
Second is the ability of TRIM5a dimers to interact with each
other and form higher-order oligomers (Diaz-Griffero et al.,
2009; Li and Sodroski, 2008). Cryo-electron microscopy studies
of recombinant purified TRIM5a revealed that the protein can
assemble into 2D arrays, the hexagonal symmetry of which
matches the symmetry of the assembled retroviral capsid
(Diaz-Griffero, 2011; Ganser-Pornillos et al., 2011). Mutations
in the B-box domain that disrupt such higher-order oligomeriza-
tion also impair restriction (Diaz-Griffero et al., 2009; Li and
Sodroski, 2008). The assembly of TRIM5a is promoted by the
assembled HIV capsid, and it was suggested that TRIM5a
may form cage-like structures enclosing retroviral cores in the
cytoplasm, but the importance of such putative higher-order
structures for HIV restriction has not been explored.
Third, the E3 ubiquitin ligase activity of TRIM proteins is a key
element of their biological function, albeit the exact role it plays in
TRIM5a-mediated retroviral restriction is less well understood.
For example, proteasome inhibition (Anderson et al., 2006;
Diaz-Griffero et al., 2006b; Perez-Caballero et al., 2005; Wu
et al., 2006) or mutations in the RING domain of TRIM5a (Roa
et al., 2012) abolish accelerated uncoating of the retroviral
capsid (Stremlau et al., 2006) and the reverse transcription
defect caused by TRIM5a (Keckesova et al., 2004; Stremlau
et al., 2004), but they do not relieve TRIM5a-mediated replication
block, suggesting that TRIM5a may interfere with the early
events of retroviral replication in more than one way.
In a recent study, TRIM5 was shown to catalyze synthesis
of K63-linked polyubiquitin chains and to induce activation of
innate immunity pathways (Pertel et al., 2011). Synthesis of
K63-linked polyubiquitin by the owl monkey TRIMCyp variant
of TRIM5was greatly enhanced by the addition of the assembled
HIV capsid in a reconstituted assay. It was suggested that TRIM5
may act as a pattern recognition receptor, the E3 Ub ligase activ-
ity of which is stimulated by the interaction with a retroviral path-
ogen-associated molecular pattern (PAMP)—the capsid. Similar
ability to activate innate immunity signaling by promoting synthe-
sis of K63-linked Ub chains in a ligand-dependent manner has
been reported for TRIM21 (McEwan et al., 2013) and TRIM25
(Gack et al., 2007; Zeng et al., 2010). Molecular basis of TRIM
involvement in PAMP recognition and the mechanism linking
the E3 activity and the SPRY-mediated interaction with the
ligand remain unknown.
In this study, we focus on the ability of TRIM5a to catalyze syn-
thesis of K63-linked polyubiquitin and describe a mechanism
controlling E3 ubiquitin ligase activity in the TRIM family. The
mechanism involves transient dimerization of the RING domain
and links higher-order self-assembly of TRIM5a, promoted by
the interaction with the HIV capsid, to polyubiquitin synthesis.
RESULTS
RING Promotes Polyubiquitin Synthesis by a Number of
E2 Proteins, but Only Ubc13 Plays a Non-redundant Role
in Retroviral Restriction
Previous reports have suggested a role for ubiquitylation in the
ability of TRIM5arh to restrict HIV-1 (Kim et al., 2011; Lienlaf
et al., 2011; Maegawa et al., 2010; Pertel et al., 2011; Rold and
Aiken, 2008). Here, we surveyed the ability of different E2
enzymes to promote TRIM5arh-depedent synthesis of polyubi-
quitin chains. For this purpose, we used the standard in vitro pol-
yubiquitin synthesis assay (Pickart and Raasi, 2005) with the
TRIM5arh RING domain (residues 1–93) fused to glutathione-
S-transferase (GST-RING1–93) to test the ability of a set of
commercially available recombinant human E2 enzymes to cata-
lyze polyubiquitin synthesis in the presence of GST-RING1–93
(Figures 1A and S1A). In vitro assays are known to polyubiquity-
late RING domains as well as generate free polyubiquitin chains
so the products of the reaction were visualized with both anti-
GST antibodies to detect RING self-polyubiquitylation and
with anti-myc antibodies to detectmyc-taggedUb. These exper-
iments showed that UbcH5a, UbcH5b, UbcH5c, UbcH6, Ube2S,
and Ube2E3 strongly catalyzed synthesis of polyubiquitin chains
in the presence of GST-RING1–93, whereas UbcH10 and Ube2T
displayed weaker activity. We also observed synthesis ofpolyubiquitin chains by Ubc13/Uev1a in the presence of GST-
RING1–93 and full-length recombinant TRIM5a (Figures 1A and
S1C) in agreement with previous findings (Pertel et al., 2011).
To test whether the E2 enzymes capable of promoting synthe-
sis of polyubiquitin chains with TRIM5arh RING contribute to the
ability of TRIM5a to block retroviral infection, we tested restric-
tion in human HT1080 cells silenced for the indicated E2
enzymes. Because our preliminary experiments revealed that
the knockdown of some E2 proteins blocks the infection of
HIV-1 and N-MLV, we measured the ability of human TRIM5a
(TRIM5ahu) to block infection of equine infectious anemia virus
(EIAV), as previously described (Diaz-Griffero et al., 2008).
Depletion of the different E2s in human HT1080 cells revealed
that only depletion of Ubc13 decreased the ability of TRIM5ahu
to block EIAV-GFP infection (Figure 1B). As a control, we show
that depletion of TRIM5ahu completely restores EIAV infection
in HT1080 cells. This finding is in agreement with previous obser-
vations (Pertel et al., 2011) and suggests that the non-redundant
role of Ubc13 in the synthesis of K63-linked polyubiquitin
contributes to the anti-EIAV activity of TRIM5ahu in human cells.
The potential role of other E2s in the antiretroviral function of
TRIM5a cannot be ascertained from these data because of
possible functional redundancy of different E2 enzymes. As the
key role of K63-linked polyubiquitin synthesis in the function of
several other TRIM family members has been described in
previous studies (Gack et al., 2007; McEwan et al., 2013; Zeng
et al., 2010), we focused here on the Ubc13-mediated E3 activity
of TRIM5a.
For the structural and mechanistic studies described below,
we expressed and purified recombinant TRIM5a RING1–93;
untagged ubiquitin; and E2 proteins UbcH5c, Ubc13, and
Mms2 using bacterial expression vectors. We then tested the
in vitro ubiquitin conjugation activity of the recombinant proteins
produced for structural studies. In agreement with the results
described above, TRIM5a RING1–93 can stimulate synthesis of
polyubiquitin chains with Ubc13 and UbcH5c (Figure 1C). Sur-
prisingly, we observed that the TRIM5a RING1–93 can synthesize
polyubiquitin chains with Ubc13 in the absence of Mms2
or Uev1a, E2 variant proteins known to heterodimerize with
Ubc13 and promote synthesis of K63-linked polyubiquitin (Fig-
ure 1C, lanes 5 and 6). The ability of TRIM5aRING1–93 to promote
synthesis of K63-linked Ub chains with Ubc13 alone simplified
our in vitro conjugation assays because it obviated the need to
take into account the background activity of the Ubc13/Mms2
complex, an issue that we had to address in the E2 survey
described above (Supplemental Experimental Procedures).
The efficiency of the conjugation reaction catalyzed by TRIM5a
RING1–93 and Ubc13 was comparable to that of the Ubc13/
Mms2 complex (Figure 1C, lanes 3 and 4), which was used as
a positive control. We also investigated the type of polyubiquitin
linkage generated in the in vitro reactions by western blot using
K63- and K48-linkage-specific antibodies (Figure 1C, left panel
and right panel, respectively). Polyubiquitin chains synthesized
by TRIM5a RING1–93 and UbcH5c can be visualized by both
antibodies because UbcH5c is a promiscuous E2 protein that
generates both K48 and K63 linkages in vitro (Brzovic and Klevit,
2006; Kirkpatrick et al., 2006). In contrast, polyubiquitin synthe-
sized by TRIM5a RING1–93 and Ubc13 appears to be strictly K63Cell Reports 12, 788–797, August 4, 2015 ª2015 The Authors 789
Figure 1. E3 Ubiquitin Ligase Activity of the
TRIM5a RING
(A) Survey of the TRIM5a GST-RING1–93 E3 Ub
ligase activity with a panel of E2-conjugating
proteins. Formation of polyubiquitin chains was
visualized by western blot using either anti-Myc or
anti-GST antibodies.
(B) siRNA depletion of a panel of E2 proteins
reveals that Ubc13 is required for the ability of
the human TRIM5a to block infection of equine
infectious anemia virus (EIAV).
(C) Linkage specificity of the TRIM5a RING-
catalyzed polyubiquitin chains. Western blots with
K63-linkage-specific and K48-linkage-specific
antibodies reveal that the polyubiquitin chains
formed in the presence of TRIM5a RING and
Ubc13 are K63 linked.
See also Figure S1.linked as is the case for the Ubc13/Mms2 control. This finding is
intriguing because heterodimerization of Ubc13with non-canon-
ical E2 variants (Mms2 or Uev1a) is believed to play a key role in
determining linkage specificity (Eddins et al., 2006).
Crystal Structure of the TRIM5a RING:Ubc13 Complex
Reveals Canonical E3:E2 Interface in which the Central
a Helix of the RING Domain Is Disordered
In order to elucidate structural basis of Ubc13 activation by the
TRIM5a RING domain, we determined the crystal structure of
the complex formed by the TRIM5arh RING1–93 and Ubc13 (Fig-
ure 2; see Supplemental Experimental Procedures).
TRIM5aRINGandUbc13 interact via thecanonicalRINGE3:E2
interface formed between the Zn-coordinating loops of the RING
domain and the E2 surface formed by helix1 and the extended790 Cell Reports 12, 788–797, August 4, 2015 ª2015 The Authorsloop segment located between the cata-
lytic cysteine C87 and helix2. Figure 2B
shows key residues contributing to shape
complementarity of the two protein sur-
faces. We previously identified several
RING mutants that alter the restriction
activity of TRIM5a. For example, the
R60A mutation is strongly detrimental to
the HIV-1 restriction activity of TRIM5arh,
whereas the Y63E mutation abolishes
accelerated uncoating and restores
normal RT but has only a veryminor effect
on restriction (Lienlaf et al., 2011; Roa
et al., 2012). The structure reveals that
thesidechainofR60 formsakeyhydrogen
bond with the backbone carbonyl of
Ubc13 K94. Analogous hydrogen bond
bridgewaspreviously shown tocontribute
to activation of UbcH5-Ub conjugates
by RING E3 Ub ligases (see Discussion;
Dou et al., 2012; Plechanovova´ et al.,
2012; Pruneda et al., 2012).
The main difference between the
TRIM5a RING:Ubc13 complex and thepreviously determined structures of RING E3:E2 pairs is in
the role played by the central a helix of the RING domain. The
central a helix is well resolved in all known RING:E2 crystal struc-
tures, including two RING:Ubc13 complexes (Campbell et al.,
2012; Yin et al., 2009), and contributes to the E3:E2 interfaces
by making van der Waals contacts with E2, particularly with
the long-chain hydrophobic residue located in the loop between
b strands 3 and 4 (residue M64 in Ubc13). In contrast, the central
a helix is largely disordered in the TRIM5a RING:Ubc13 struc-
ture, suggesting that interactions of the central a helix do not
provide a major contribution to the stability of the TRIM5a
RING:Ubc13 complex.
Residue Y63 of TRIM5aRING is a key residue of the hydropho-
bic interface between the central a helix and the core of the RING
domain and is likely to be important for RING:E2 interactions
Figure 2. Structure of the TRIM5a RING:Ubc13 Complex
(A) Ubc13 is shown in green/olive and TRIM5a RING in blue/cyan with Zn2+ ions rendered as gray spheres. Two adjacent RING:Ubc13 complexes are shown in
order to reveal the RING dimer formed in the crystal. RING dimerization is mediated by the four-helix bundle arrangement of the N-terminal and C-terminal
amphipathic helices.
(B) Cartoon representation of the E3:E2 interface showing key residues contributing to the E3:E2 interaction. A segment of the RING domain (amino acids 40–54)
that includes most of the central helix is disordered in the crystal and is shown in the figure as a gray backbone trace modeled using the NMR structure of the
human TRIM5a RING.
(C) Expanded view of the RING dimer interface. Cartoon representation of one of the a helices forming the four-helix bundle is removed for clarity, leaving only the
side chains that contribute to the hydrophobic interior of the bundle.
(D) Multiple sequence alignment of the rhesus TRIM5aRING (top sequence) with RING domains from 30 human TRIM proteins shown in the logo format. Location
of the three helical elements in the TRIM5a RING structure is shown above the sequence. I77 (marked with red asterisk) is a key residue of the dimer interface.
I77R mutation was used to test the functional role of RING dimerization.
(E) Van Holde-Weischet analysis of the velocity sedimentation data obtained for the RING, RING-Bbox, and RING-Bbox (R121E) samples.
See also Figure S2 and Table S1.mediated by the central helix. In agreement with these structural
observations, in vitro polyubiquitylation assays revealed that the
Y63E mutation appears to be more detrimental for the TRIM5a
RING E3 activity with UbcH5 than with Ubc13 (Figure S1C).
These data further support the unique role of Ubc13 as a key
contributor to retroviral restriction.
Crystal Structure of the TRIM5a RING:Ubc13 Complex
Reveals Dimerization of the RING Domain
The key insight of the study is provided by the observation that
TRIM5a RING forms a dimer in the crystal (Figure 2). The dimer
interface is formed by the four-helix bundle arrangement of the
N-terminal and C-terminal a helices flanking the amino acid
sequence of the Zn-binding core of the RINGdomain (Figure 2C).
This dimerization mode is similar to the one observed in the
BRCA-1/BARD-1 RING heterodimer (Brzovic et al., 2001) and
places TRIM5a RING in the class of RING dimers, in which se-
quences located outside of the Zn-binding core of the RING
domain are primarily responsible for dimerization (Metzger
et al., 2014).Inspection of the amino acid conservation patterns within the
RING domain in a selection of 30 human TRIM proteins indicates
that this dimerization mode is conserved in the majority of the
human TRIM family members. Multiple sequence alignment
was performed using ClustalW program (Figure S2A) (Larkin
et al., 2007), and the logo representation was generated using
the WebLogo application (Figure 2D) (Crooks et al., 2004). In
most of the TRIM proteins used in the alignment, the amino
acid segments flanking the RING domain display a pattern of hy-
drophobic and hydrophilic residues characteristic of two amphi-
pathic a helices. The hydrophobic side chains project within the
interior of the four-helix bundle in the TRIM5aRING structure and
contribute to the predominantly hydrophobic dimer interface.
The relative position of adjacent helices within the bundle is
maintained by cross-interface hydrogen bonds. Of particular
notice is the hydrogen bond bridge formed by two N71 residues
(one from each monomer) located at the N-terminal tip of the
C-terminal a helix. N71 is conserved in most human TRIM pro-
teins. Finally, the crystal structure of the TRIM37 RING domain
determined by the Northeast Structural Genomics ConsortiumCell Reports 12, 788–797, August 4, 2015 ª2015 The Authors 791
(PDB: 3LRQ) reveals a RING dimer very similar to the one we
observe in the TRIM5a RING structure (Figure S2B), further sup-
porting that RING dimerization is a conserved property of TRIM
proteins.
We used analytical ultracentrifugation to investigate dimeriza-
tion of the RING domain in solution. Sedimentation velocity
experiments revealed that the diffusion-corrected van Holde-
Weischet sedimentation coefficient distribution of the TRIM5a
RING1–93 sample is indicative of a single species (Figure 2E).
Genetic algorithm-Monte Carlo analysis (GA-MC) (Brookes and
Demeler, 2007; Demeler andBrookes, 2008) reveals a single spe-
cies with 93% of the concentration evaluating to a molecular
weight of 11.4 kDa, in close agreement with the theoretical mo-
lecular weight of the monomer (Figure S2C). Thus, despite the
extensive hydrophobic interface formed by the four-helix bundle
in the crystal, the TRIM5aRING1–93 construct used for crystalliza-
tion is monomeric in solution up to concentrations of 2 mg/ml.
In contrast, a longer construct that encompasses both the
RING and B-box domains (TRIM5a RING-Bbox1–135) displays
sedimentation coefficient heterogeneity indicative of protein
oligomerization (Figure 2E). The oligomerization of the RING-
Bbox1–135 construct is significantly reduced by the R121E muta-
tionwithin theB-box domain known to interferewith higher-order
TRIM5a assembly and restriction (Diaz-Griffero et al., 2007,
2009). The analytical ultracentrifugation data suggest that inter-
actionsmediatedby theB-boxof TRIM5aaremost likely required
for the formation of theRINGdimer in the context of the full-length
TRIM5a at physiological concentrations.
TRIM5a RING Dimer Promotes Polyubiquitin Synthesis
by Stabilizing the ‘‘Closed’’ Conformation of the
Ubc13-Ub Conjugate
Although the ability to form homo- and heterodimers is a
commonly observed and functionally important property of
RING domains, themechanism bywhich RINGdimerization con-
tributes to the E3 Ub ligase function remained elusive until three
recent studies provided the first glimpses at an E3:E2 complex
poised to transfer ubiquitin (Dou et al., 2012; Plechanovova´
et al., 2012; Pruneda et al., 2012). The studies performed on
E2-Ub conjugates of the UbcH5 family (Ube2D1–3) in complex
with RING E3s revealed that RING dimer promotes Ub transfer
by stabilizing particular relative orientation of Ub and E2, known
as the ‘‘closed’’ conformation. In order to elucidate whether a
similar mechanism may be involved in the activation of Ubc13
by TRIM5a, we explored the interaction between the TRIM5a
RING and the Ubc13-Ub conjugate using NMR (see Supple-
mental Experimental Procedures).
The effect of RING dimerization on the RING:Ubc13-Ub inter-
action was investigated using two modified RING constructs. In
one, a stabilized RING dimer was created by making a tandem
RING protein in which two RING domains follow each other in
a single polypeptide chain. The other construct contained the
I77R mutation in the RING monomer. I77 points into the hydro-
phobic interior of the four-helix bundle of the RING dimer, and
the I77R mutation is expected to disrupt dimerization (see Sup-
plemental Experimental Procedures).
When the tandem RING is added to the Ubc13-Ub
conjugate, in which Ubc13 is 15N labeled, all signals with the792 Cell Reports 12, 788–797, August 4, 2015 ª2015 The Authorsexception of the highly mobile C terminus disappear, indicating
that Ubc13 becomes part of a high-molecular-weight complex
(Figure 3A). The same is true for the ubiquitin-labeled
conjugate, because upon addition of the RING dimer only
NMR signals of free ubiquitin are observed whereas all NMR
signals arising from the conjugate are broadened beyond
detection sensitivity (Figure 3B). Free ubiquitin accumulates
because addition of the RING dimer promotes slow hydro-
lysis of the otherwise stable ester-linked Ubc13(C87S)-Ub
conjugate.
In contrast, when the I77R RING is added to the Ubc13-Ub
conjugate, the NMR signals are not detectably broadened and
only very minor chemical shift changes are observed in the
spectra (Figures 3C and 3D). This is characteristic of a weak
protein-protein interaction occurring in the fast exchange
regime. Location of the most perturbed residues in Ub and
Ubc13 and their chemical shift perturbations indicate that
TRIM5a RING interacts with the closed conformation of the
Ubc13-Ub conjugate (Figure 3F). Collectively, our data strongly
suggest that TRIM5a RING dimerization promotes Ubc13-Ub
binding and that the structural basis of Ubc13-Ub conjugate
activation by TRIM5a RING is analogous to the mechanism
of UbcH5a activation by RNF4 and BIRC7 (Dou et al., 2012; Ple-
chanovova´ et al., 2012).
Dimer Interface Mutation I77R Disrupts Synthesis of
K63-Linked Polyubiquitin Chains and Impairs
Restriction
Impact of the I77R mutation on the E3 Ub ligase activity of
TRIM5a RING was tested in an in vitro polyubiquitin synthesis
assay. We observe that the ability of TRIM5a RING to promote
synthesis of K63-linked chains by Ubc13 is completely
blocked by the I77R mutation (Figure 4A). In contrast, when
the E3 ligase activity of I77R RING is tested with UbcH5c,
polyubiquitin can still be synthesized, albeit with reduced effi-
ciency. Dimerization of TRIM5a RING is, therefore, not strictly
required for the UbcH5c-mediated ubiquitin conjugation activ-
ity, but it does enhance the reaction rate. UbcH5 is known for
its ability to promote synthesis of ubiquitin chains in vitro in the
presence of most UbcH5-interacting RING domains, regard-
less of their dimerization status. The UbcH5 data indicate
that the I77R RING is a folded protein that can still form the
E3:E2 complex.
Finally, we measured the effect of the I77R mutation on the
HIV restriction activity of the full-length TRIM5a. Cf2Th cells sta-
bly expressing WT, and the indicated mutant TRIM5a proteins
were incubated with increasing amounts of HIV-1-GFP (Fig-
ure 4B). Infection was determined by measuring the percentage
of GFP-positive cells. Infection experiments revealed that the re-
striction activity of the I77R mutant is significantly reduced, and
the restriction defect of I77R is even more pronounced than that
of the R60A mutation (Lienlaf et al., 2011). R60 is a key residue
required for activation of E2-Ub conjugate by RING domain
dimers (Dou et al., 2012; Plechanovova´ et al., 2012; Pruneda
et al., 2012), and the R60A mutation was previously shown to
abolish E3 ligase activity of TRIM5a in vitro (Lienlaf et al.,
2011). These data demonstrate the role of RING dimerization in
the retroviral restriction by TRIM5a.
Figure 3. Activation of the Ubc13-Ub Conjugate by TRIM5a RING
(A–D) NMR studies of Ubc13-Ub and TRIM5a RING binding. Overlays of 15N HSQC spectra of Ubc13-Ub conjugate before (red) and after (green) addition of
equimolar amounts of TRIM5aRING constructs. Overlapping signals appear black. (A andC) Ubc13-labeled Ubc13-Ub conjugate is shown. (B and D) Ub-labeled
Ubc13-Ub conjugate is shown. Binding experiments were performed with a stabilized tandem RING dimer (A and B) and with the I77R RINGmonomer (C and D).
(E) TRIM5aRING dimer activates the Ubc13-Ub conjugate by stabilizing the ‘‘closed’’ conformation of the conjugate via themechanism analogous to activation of
UbcH5-Ub by RNF4 or BIRC7 (Lima and Schulman, 2012).
(F) Model of the TRIM5aRING:Ubc13-Ub complex. Ubiquitin wasmodeled onto the TRIM5aRING:Ubc13 complex by aligning the TRIM5aRING:Ubc13 structure
with the BIRC7:UbcH5-Ub complex (PDB: 4AUQ). The high structural homology of UbcH5 andUbc13was used for alignment. Themost-perturbed residues in the
experiments shown in (C) and (D) are highlighted red in the model.
See also Figure S3.DISCUSSION
The key finding of this study is that TRIM5a RING can form a
dimer and that RING dimerization is required for synthesis of
K63-linked Ub chains by the TRIM5a RING:Ubc13 E3:E2 pair.
RING dimerization is a commonly observed phenomenon in
the RING-containing class of E3 ubiquitin ligases, and it has
recently been shown that RING domain dimers of RNF4, E4B,
and BIRC7 activate E2-Ub conjugates formed by the E2s of
the UbcH5 family during synthesis of K48-linked polyubiquitin
chains (Dou et al., 2012; Plechanovova´ et al., 2012; Pruneda
et al., 2012). We show here that activation of the Ubc13-Ub con-
jugate by the TRIM5a RING dimer also involves stabilization of
the so-called closed state of the Ubc13-Ub conjugate and a
critical hydrogen bond bridge formed by a key RING residue
(R60 in TRIM5arh) between the C-terminal segment of ubiquitin
and backbone carbonyl of K94 in Ubc13. Our findings demon-
strate that this activation mechanism is not limited to the E2s
of the UbcH5 family and to RING dimers from the RNF4 and
E4B class, in which the dimerization mode is distinct from that
of the TRIM5a RING. Our data indicate that the activated
conformation of the donor Ub in the E2-Ub conjugate isa conserved feature of the ubiquitin conjugation mechanism
irrespective of the type of linkage generated by a particular
RING:E2 pair.
Albeit RING dimerization is common in E3 ubiquitin ligases
and important for E2-Ub activation, the potential role of RING
dimerization in the regulation of E3 activity has remained
elusive. The critical role of RING dimerization in polyubiquitin
synthesis by TRIM5a suggests a mechanism of E3 activation
(Figure 5). Structural and biochemical properties of TRIM pro-
teins explain how RING dimerization acts as the key element
linking E3 activity to ligand binding. Recently determined struc-
tures of the TRIM25 and TRIM5 coiled-coil dimers revealed that
the RING and B-box domains of each TRIM monomer within
the TRIM dimer must be located on the opposing ends of the
long, rod-shaped molecule (Goldstone et al., 2014; Sanchez
et al., 2014). It is, therefore, most likely that the RING dimer
is formed between two TRIM dimers as a result of higher-order
TRIM oligomerization. This model is supported by the observa-
tions that higher-order oligomerization of TRIM5a is required for
restriction (Diaz-Griffero et al., 2009; Ganser-Pornillos et al.,
2011; Li and Sodroski, 2008). We show here that RING dimer-
ization is not energetically favorable and that the two RINGCell Reports 12, 788–797, August 4, 2015 ª2015 The Authors 793
Figure 4. Functional Impact of the I77R Dimer-Interface Mutation
(A) Western blot analysis of the in vitro Ub conjugation reaction reveals that
synthesis of K63-linked polyubiquitin chains is disrupted by the I77R mutation
in the TRIM5arh RING1–93. In contrast, synthesis of the polyubiquitin chains in
the presence of UbcH5c is less efficient, but not completely blocked.
(B) Restriction of HIV-1 infection by the WT and RING domain mutants of
TRIM5arh. Cf2Th cells stably expressing WT and mutant TRIM5arh were
challenged with increasing amounts of HIV-1-GFT as described in Experi-
mental Procedures. Percentage of GFP-positive cells after 48 hr was
measured by FACS. WT and mutant TRIM5a constructs were expressed at
similar levels as evidenced by western blot.modules have to be brought in proximity by the action of other
protein-protein interactions. Formation of the higher-order
structures by TRIM5a is enhanced by the presence of the
assembled capsid, suggesting that higher-order oligomeriza-
tion of TRIM5a is promoted by SPRY-mediated interactions
with the capsid template (Ganser-Pornillos et al., 2011). In the
model we propose (Figure 5), two TRIM dimers have to be
bound in proximity to each other, which puts certain restraints
on the distance and/or relative orientation between TRIM-
binding epitopes. The resulting cooperativity between ligand
binding and RING dimerization provides the mechanistic link
between epitope recognition by TRIM proteins and the activa-
tion of their E3 Ub ligase function, which may underlie the pro-
posed role of TRIM proteins in PAMP recognition. In this study,
we show that disruption of RING dimerization in TRIM5a results
in a major defect in TRIM5a-mediated restriction of retroviral
replication.
The current model of the TRIM5a hexagonal assemblies
observed by electron microscopy places the RING and B-box
domains close to the 3-fold symmetry axis of the hexagonal lat-
tice (Figure 5D). Taken in conjunction with our data, the model
suggests that there may be a 3-fold/2-fold symmetry mismatch794 Cell Reports 12, 788–797, August 4, 2015 ª2015 The Authorspresent in the assembled structure. Albeit symmetry mis-
matches are not uncommon in largemacromolecular assemblies
(Dormitzer et al., 2004; Goodsell and Olson, 2000), particularly in
viral particles, the functional significance of such arrangement is
not immediately apparent. It is possible that two RING domains
activate the E2-Ub conjugate whereas the third one acts as an
Ub acceptor.
In summary, our study elucidates the role of RING dimeriza-
tion in the E3 ubiquitin ligase activity of the TRIM5a retroviral
restriction factor. The findings reveal how E3 ubiquitin ligase ac-
tivity can be controlled by the ligand-templated higher-order
oligomerization of TRIM5a that promotes transient dimerization
of the RING modules. The mechanism linking ligand binding
with E3 activation is likely to be conserved in many TRIM family
members and may be central to their role in innate immune
signaling.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
TRIM5a RING1–93 construct was expressed and purified as previously
described (Lienlaf et al., 2011). E2 proteins used in Ub conjugation assays
were either purchased from BostonBiochem or expressed and purified from
E.coli as described in the Supplemental Experimental Procedures.
Ubiquitin Conjugation Assays
In vitro ubiquitin conjugation assays were performed using published proto-
cols (Pickart and Raasi, 2005). Further details can be found in the Supple-
mental Experimental Procedures.
Retroviral Restriction Assays and siRNA
Cf2Th canine thymocytes stably expressing wild-type or mutant TRIM5a
proteins and recombinant HIV-1 and EIAV pseudotyped with the VSV-G glyco-
protein and expressing GFP were prepared as described (Diaz-Griffero et al.,
2008). GFP-positive cells were analyzed using a flow cytometer (Becton Dick-
inson). For transient E2 knockdown experiments, the proteins were silenced
using siRNA SMARTpools from Dharmacon. The level of expression knock-
down was determined real-time PCR using specific primers against the
different E2 proteins. Further details can be found in the Supplemental Exper-
imental Procedures.
Crystallization, Structure Determination, and Refinement
Automated screening for crystallizationwas carried out at the X-ray Crystallog-
raphy Core Laboratory at the University of Texas Health Science Center at San
Antonio. Details of data collection, structure determination, and refinement are
described in the Supplemental Experimental Procedures. Data collection and
refinement statistics are shown in Table S1.
NMR and Analytical Ultracentrifugation
NMR studies of the 15N-Ubc13-labeled and 15N-Ub-labeled Ubc13-Ub conju-
gate (0.18–0.25 mM) in either free form or in the presence of the 1:1 molar ratio
of the unlabeled WT and mutant RING proteins were carried out at 298 K
on Bruker Avance 600- and 700-MHz spectrometers by recording 1H–15N
TROSY HSQC spectra. All sedimentation experiments were performed with
a Beckman Optima XL-I at the Center for Analytical Ultracentrifugation of
Macromolecular Assemblies at the University of Texas Health Science Center
at San Antonio. Detailed description of sample preparation and data analysis
can be found in the Supplemental Experimental Procedures.
ACCESSION NUMBERS
The atomic coordinates of the TRIM5a RING:Ubc13 structure reported in this
paper have been deposited to the Protein Data Band and are available under
accession number PDB: 4TKP.
Figure 5. Model of TRIM5a Activation upon Capsid Binding
(A) Space filling model of the full-length TRIM5a assembled from structures of individual domains. Two TRIM5a dimers are shown to scale with the lateral surface
segment of the assembled HIV capsid. Capsid monomers are shown in alternating green and blue color.
(B) Interaction of TRIM5awith the capsid facilitates formation of a RING dimer between two TRIM5a dimers bound in proximity to each other. RING dimer recruits
Ubc13-Ub or other E2-Ub conjugates.
(C) RING:E2-Ub interaction activates the E2-Ub conjugate (designated E2*Ub) and promotes Ub transfer.
(D) Model of the hexagonal, higher-order TRIM5a assemblies observed by cryo-electron microscopy (Ganser-Pornillos et al., 2011; Sanchez et al., 2014). RING
dimerization may introduce a 2-fold/3-fold symmetry mismatch close to the 3-fold axis of the hexagonal lattice.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.06.072.
ACKNOWLEDGMENTS
This research was supported in part by the Collaborative Development
Award to D.N.I. from the Center for the Structural Biology of Cellular Host
Elements in Egress, Trafficking, and Assembly of HIV (CHEETAH; NIH P50
GM082545); R01 AI087390, R21 AI102824, and R56 AI108432 to F.D.-G;
Robert A. Welch Foundation grant AQ-1399 to P.J.H; NIH R01 AI104476
to D.N.I.; and Scholar Award from the Cancer Prevention and Research
Institute of Texas (CPRIT) to D.N.I. A.R., D.A.d.S.A.V., V.T., N.R., and
F.D.-G. were supported by NIH grants R01 AI087390, R21 AI102824, and
R56 AI108432 to F.D.-G. The NMR, X-ray, and Analytical Ultracentrifugation
core facilities at the UT Health Science Center at San Antonio (UTHSCSA)
are supported in part by the NIH P30 CA054174 to the Cancer Therapy
and Research Center. B.D. acknowledges support from NSF for the devel-
opment of the UltraScan Science Gateway used in the analysis of AUC data
(ACI-1339649 and TG-MCB070039). X-ray diffraction data were collected at
the Advanced Photon Source beamline 24-IDC NE-CAT funded by NIH-
NIGMS P41 GM103403 and NIH-ORIP HEI S10 RR029205 at Argonne
National Laboratory under DOE Office of Science contract no. DE-AC02-
06CH11357.
Received: December 2, 2014
Revised: May 26, 2015
Accepted: June 25, 2015
Published: July 23, 2015REFERENCES
Anderson, J.L., Campbell, E.M., Wu, X., Vandegraaff, N., Engelman, A., and
Hope, T.J. (2006). Proteasome inhibition reveals that a functional preintegra-
tion complex intermediate can be generated during restriction by diverse
TRIM5 proteins. J. Virol. 80, 9754–9760.
Biris, N., Yang, Y., Taylor, A.B., Tomashevski, A., Guo,M., Hart, P.J., Diaz-Grif-
fero, F., and Ivanov, D.N. (2012). Structure of the rhesus monkey TRIM5a
PRYSPRY domain, the HIV capsid recognition module. Proc. Natl. Acad.
Sci. USA 109, 13278–13283.
Brookes, E.H., and Demeler, B. (2007). Parsimonious regularization using
genetic algorithms applied to the analysis of analytical ultracentrifugation ex-
periments. Proceedings of the 9th Annual Conference on Genetic and Evolu-
tionary Computation, 361–368.
Brzovic, P.S., and Klevit, R.E. (2006). Ubiquitin transfer from the E2 perspec-
tive: why is UbcH5 so promiscuous? Cell Cycle 5, 2867–2873.
Brzovic, P.S., Rajagopal, P., Hoyt, D.W., King, M.C., and Klevit, R.E. (2001).
Structure of a BRCA1-BARD1 heterodimeric RING-RING complex. Nat.
Struct. Biol. 8, 833–837.
Campbell, S.J., Edwards, R.A., Leung, C.C., Neculai, D., Hodge, C.D., Dhe-
Paganon, S., and Glover, J.N. (2012). Molecular insights into the function of
RING finger (RNF)-containing proteins hRNF8 and hRNF168 in Ubc13/
Mms2-dependent ubiquitylation. J. Biol. Chem. 287, 23900–23910.
Crooks, G.E., Hon, G., Chandonia, J.M., and Brenner, S.E. (2004). WebLogo: a
sequence logo generator. Genome Res. 14, 1188–1190.
Demeler, B., and Brookes, E. (2008). Monte Carlo analysis of sedimentation
experiments. Colloid Polym. Sci. 286, 129–137.
Diaz-Griffero, F. (2011). Caging the beast: TRIM5a binding to the HIV-1 core.
Viruses 3, 423–428.Cell Reports 12, 788–797, August 4, 2015 ª2015 The Authors 795
Diaz-Griffero, F., Vandegraaff, N., Li, Y., McGee-Estrada, K., Stremlau, M.,
Welikala, S., Si, Z., Engelman, A., and Sodroski, J. (2006a). Requirements
for capsid-binding and an effector function in TRIMCyp-mediated restriction
of HIV-1. Virology 351, 404–419.
Diaz-Griffero, F., Li, X., Javanbakht, H., Song, B., Welikala, S., Stremlau, M.,
and Sodroski, J. (2006b). Rapid turnover and polyubiquitylation of the retroviral
restriction factor TRIM5. Virology 349, 300–315.
Diaz-Griffero, F., Kar, A., Perron, M., Xiang, S.H., Javanbakht, H., Li, X., and
Sodroski, J. (2007). Modulation of retroviral restriction and proteasome inhib-
itor-resistant turnover by changes in the TRIM5alpha B-box 2 domain. J. Virol.
81, 10362–10378.
Diaz-Griffero, F., Perron, M., McGee-Estrada, K., Hanna, R., Maillard, P.V.,
Trono, D., and Sodroski, J. (2008). A human TRIM5alpha B30.2/SPRY domain
mutant gains the ability to restrict and prematurely uncoat B-tropic murine leu-
kemia virus. Virology 378, 233–242.
Diaz-Griffero, F., Qin, X.R., Hayashi, F., Kigawa, T., Finzi, A., Sarnak, Z.,
Lienlaf, M., Yokoyama, S., and Sodroski, J. (2009). A B-box 2 surface patch
important for TRIM5alpha self-association, capsid binding avidity, and retro-
virus restriction. J. Virol. 83, 10737–10751.
Dormitzer, P.R., Nason, E.B., Prasad, B.V., and Harrison, S.C. (2004). Struc-
tural rearrangements in the membrane penetration protein of a non-enveloped
virus. Nature 430, 1053–1058.
Dou, H., Buetow, L., Sibbet, G.J., Cameron, K., and Huang, D.T. (2012).
BIRC7-E2 ubiquitin conjugate structure reveals the mechanism of ubiquitin
transfer by a RING dimer. Nat. Struct. Mol. Biol. 19, 876–883.
Eddins, M.J., Carlile, C.M., Gomez, K.M., Pickart, C.M., and Wolberger, C.
(2006). Mms2-Ubc13 covalently bound to ubiquitin reveals the structural basis
of linkage-specific polyubiquitin chain formation. Nat. Struct. Mol. Biol. 13,
915–920.
Gack, M.U., Shin, Y.C., Joo, C.H., Urano, T., Liang, C., Sun, L., Takeuchi, O.,
Akira, S., Chen, Z., Inoue, S., and Jung, J.U. (2007). TRIM25 RING-finger E3
ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446,
916–920.
Ganser-Pornillos, B.K., Chandrasekaran, V., Pornillos, O., Sodroski, J.G.,
Sundquist, W.I., and Yeager, M. (2011). Hexagonal assembly of a restricting
TRIM5alpha protein. Proc. Natl. Acad. Sci. USA 108, 534–539.
Goldstone, D.C., Walker, P.A., Calder, L.J., Coombs, P.J., Kirkpatrick, J., Ball,
N.J., Hilditch, L., Yap, M.W., Rosenthal, P.B., Stoye, J.P., and Taylor, I.A.
(2014). Structural studies of postentry restriction factors reveal antiparallel di-
mers that enable avid binding to the HIV-1 capsid lattice. Proc. Natl. Acad. Sci.
USA 111, 9609–9614.
Goodsell, D.S., and Olson, A.J. (2000). Structural symmetry and protein func-
tion. Annu. Rev. Biophys. Biomol. Struct. 29, 105–153.
Kar, A.K., Diaz-Griffero, F., Li, Y., Li, X., and Sodroski, J. (2008). Biochemical
and biophysical characterization of a chimeric TRIM21-TRIM5alpha protein.
J. Virol. 82, 11669–11681.
Keckesova, Z., Ylinen, L.M., and Towers, G.J. (2004). The human and African
green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction
factor activities. Proc. Natl. Acad. Sci. USA 101, 10780–10785.
Kim, J., Tipper, C., and Sodroski, J. (2011). Role of TRIM5a RING domain E3
ubiquitin ligase activity in capsid disassembly, reverse transcription blockade,
and restriction of simian immunodeficiency virus. J. Virol. 85, 8116–8132.
Kirkpatrick, D.S., Hathaway, N.A., Hanna, J., Elsasser, S., Rush, J., Finley, D.,
King, R.W., and Gygi, S.P. (2006). Quantitative analysis of in vitro ubiquitinated
cyclin B1 reveals complex chain topology. Nat. Cell Biol. 8, 700–710.
Langelier, C.R., Sandrin, V., Eckert, D.M., Christensen, D.E., Chandrasekaran,
V., Alam, S.L., Aiken, C., Olsen, J.C., Kar, A.K., Sodroski, J.G., and Sundquist,
W.I. (2008). Biochemical characterization of a recombinant TRIM5alpha pro-
tein that restricts human immunodeficiency virus type 1 replication. J. Virol.
82, 11682–11694.
Larkin, M.A., Blackshields, G., Brown, N.P., Chenna, R., McGettigan, P.A.,
McWilliam, H., Valentin, F., Wallace, I.M., Wilm, A., Lopez, R., et al. (2007).
Clustal W and Clustal X version 2.0. Bioinformatics 23, 2947–2948.796 Cell Reports 12, 788–797, August 4, 2015 ª2015 The AuthorsLi, X., and Sodroski, J. (2008). The TRIM5alpha B-box 2 domain promotes
cooperative binding to the retroviral capsid by mediating higher-order self-
association. J. Virol. 82, 11495–11502.
Lienlaf, M., Hayashi, F., Di Nunzio, F., Tochio, N., Kigawa, T., Yokoyama, S.,
and Diaz-Griffero, F. (2011). Contribution of E3-ubiquitin ligase activity
to HIV-1 restriction by TRIM5alpha(rh): structure of the RING domain of
TRIM5alpha. J. Virol. 85, 8725–8737.
Lima, C.D., and Schulman, B.A. (2012). Structural biology: A protein engage-
ment RING. Nature 489, 43–44.
Maegawa, H., Miyamoto, T., Sakuragi, J., Shioda, T., and Nakayama, E.E.
(2010). Contribution of RING domain to retrovirus restriction by TRIM5alpha
depends on combination of host and virus. Virology 399, 212–220.
McEwan, W.A., Tam, J.C., Watkinson, R.E., Bidgood, S.R., Mallery, D.L., and
James, L.C. (2013). Intracellular antibody-bound pathogens stimulate immune
signaling via the Fc receptor TRIM21. Nat. Immunol. 14, 327–336.
McNab, F.W., Rajsbaum, R., Stoye, J.P., and O’Garra, A. (2011). Tripartite-
motif proteins and innate immune regulation. Curr. Opin. Immunol. 23, 46–56.
Metzger, M.B., Pruneda, J.N., Klevit, R.E., and Weissman, A.M. (2014). RING-
type E3 ligases: master manipulators of E2 ubiquitin-conjugating enzymes and
ubiquitination. Biochim. Biophys. Acta 1843, 47–60.
Ohkura, S., Yap, M.W., Sheldon, T., and Stoye, J.P. (2006). All three variable
regions of the TRIM5alpha B30.2 domain can contribute to the specificity of
retrovirus restriction. J. Virol. 80, 8554–8565.
Perez-Caballero, D., Hatziioannou, T., Zhang, F., Cowan, S., and Bieniasz,
P.D. (2005). Restriction of human immunodeficiency virus type 1 by TRIM-
CypA occurs with rapid kinetics and independently of cytoplasmic bodies,
ubiquitin, and proteasome activity. J. Virol. 79, 15567–15572.
Pertel, T., Hausmann, S., Morger, D., Zu¨ger, S., Guerra, J., Lascano, J., Rein-
hard, C., Santoni, F.A., Uchil, P.D., Chatel, L., et al. (2011). TRIM5 is an innate
immune sensor for the retrovirus capsid lattice. Nature 472, 361–365.
Pickart, C.M., and Raasi, S. (2005). Controlled synthesis of polyubiquitin
chains. Methods Enzymol. 399, 21–36.
Plechanovova´, A., Jaffray, E.G., Tatham, M.H., Naismith, J.H., and Hay, R.T.
(2012). Structure of a RING E3 ligase and ubiquitin-loaded E2 primed for catal-
ysis. Nature 489, 115–120.
Pruneda, J.N., Littlefield, P.J., Soss, S.E., Nordquist, K.A., Chazin, W.J.,
Brzovic, P.S., and Klevit, R.E. (2012). Structure of an E3:E2Ub complex re-
veals an allosteric mechanism shared among RING/U-box ligases. Mol. Cell
47, 933–942.
Roa, A., Hayashi, F., Yang, Y., Lienlaf, M., Zhou, J., Shi, J., Watanabe, S., Ki-
gawa, T., Yokoyama, S., Aiken, C., and Diaz-Griffero, F. (2012). RING domain
mutations uncouple TRIM5a restriction of HIV-1 from inhibition of reverse tran-
scription and acceleration of uncoating. J. Virol. 86, 1717–1727.
Rold, C.J., and Aiken, C. (2008). Proteasomal degradation of TRIM5alpha dur-
ing retrovirus restriction. PLoS Pathog. 4, e1000074.
Sanchez, J.G., Okreglicka, K., Chandrasekaran, V., Welker, J.M., Sundquist,
W.I., and Pornillos, O. (2014). The tripartite motif coiled-coil is an elongated
antiparallel hairpin dimer. Proc. Natl. Acad. Sci. USA 111, 2494–2499.
Sardiello, M., Cairo, S., Fontanella, B., Ballabio, A., and Meroni, G. (2008).
Genomic analysis of the TRIM family reveals two groups of genes with distinct
evolutionary properties. BMC Evol. Biol. 8, 225.
Sebastian, S., and Luban, J. (2005). TRIM5alpha selectively binds a restriction-
sensitive retroviral capsid. Retrovirology 2, 40.
Song, B., Gold, B., O’Huigin, C., Javanbakht, H., Li, X., Stremlau, M., Winkler,
C., Dean,M., and Sodroski, J. (2005). The B30.2(SPRY) domain of the retroviral
restriction factor TRIM5alpha exhibits lineage-specific length and sequence
variation in primates. J. Virol. 79, 6111–6121.
Stremlau, M., Owens, C.M., Perron, M.J., Kiessling, M., Autissier, P., and
Sodroski, J. (2004). The cytoplasmic body component TRIM5alpha restricts
HIV-1 infection in Old World monkeys. Nature 427, 848–853.
Stremlau, M., Perron, M., Lee, M., Li, Y., Song, B., Javanbakht, H., Diaz-Grif-
fero, F., Anderson, D.J., Sundquist, W.I., and Sodroski, J. (2006). Specific
recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha
restriction factor. Proc. Natl. Acad. Sci. USA 103, 5514–5519.
Wu, X., Anderson, J.L., Campbell, E.M., Joseph, A.M., and Hope, T.J. (2006).
Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1
reverse transcription and infection. Proc. Natl. Acad. Sci. USA 103, 7465–
7470.Yin, Q., Lin, S.C., Lamothe, B., Lu, M., Lo, Y.C., Hura, G., Zheng, L., Rich, R.L.,
Campos, A.D., Myszka, D.G., et al. (2009). E2 interaction and dimerization in
the crystal structure of TRAF6. Nat. Struct. Mol. Biol. 16, 658–666.
Zeng, W., Sun, L., Jiang, X., Chen, X., Hou, F., Adhikari, A., Xu, M., and Chen,
Z.J. (2010). Reconstitution of the RIG-I pathway reveals a signaling role of
unanchored polyubiquitin chains in innate immunity. Cell 141, 315–330.Cell Reports 12, 788–797, August 4, 2015 ª2015 The Authors 797
